TheEdgeResearch
Home / Stocks / GUTS

Fractyl Health, Inc. (GUTS)

NASDAQ Healthcare Biotechnology
$0.86 ▼ -5.51%
Market Cap
$62.1M
Sector
Healthcare
Industry
Biotechnology
Beta
2.29
52-Wk Range
0.377-2.445
CEO
Harith Rajagopalan
Country
US
Currency
USD

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet c…

Open full interactive analysis & DCF →